• Slide title

    Write your caption here
    Button
  • Slide title

    Write your caption here
    Button
  • Slide title

    Write your caption here
    Button
  • Slide title

    Write your caption here
    Button
  • Slide title

    Write your caption here
    Button
  • Slide title

    Write your caption here
    Button
  • Slide title

    Write your caption here
    Button
  • Slide title

    Write your caption here
    Button

New hope for early detection.

With a cancer diagnosis, early detection can be a matter of life and death. At Syantra, that urgency is what drives us, day-in and day-out. And that drive is paying off. We’re changing the way cancer is detected and treated, starting with breast cancer.

Learn more about our blood test for breast cancer screening: Syantra DX™ Breast Cancer.

What is Syantra DX™ Breast Cancer?

It’s a blood test for breast cancer screening that’s easy, convenient and accurate.

How does it work?

Syantra DX™ Breast Cancer is a precision medicine tool that measures a panel of gene expression biomarkers from whole blood. It then uses a software package, developed with machine learning, to interpret data and provide a positive or negative result. 


Syantra DX™ Breast Cancer is a molecular approach to breast cancer screening that can detect invasive disease at early stages.

Both cancer and dense breast tissue appear white on mammograms, creating a camouflage effect. For women with extremely dense breasts, mammograms have a sensitivity of just 50%.

Syantra DX™ Breast Cancer has an inferred 98.5% accuracy for women under 50 and a 92.2% accuracy overall in ongoing prospective clinical studies.

Learn more
Syantra breast cancer blood test prediction accuracy

Accuracy

Inferred 98.5% accuracy for women under 50.⁶

Syantra breast cancer blood test prediction sensitivity

Accuracy

Inferred 92.2% accuracy for women aged 25-80 years .⁶

Clinical Study: International Identify Breast Cancer (IDBC) Study

Clinical studies are ongoing in Calgary, Canada; Manchester, UK; and Seoul, South Korea.

Through the ongoing IDBC prospective international clinical study (NCT04495244), whole blood samples (2.5 ml) from 2,100 participants are being analyzed using Syantra DX™ Breast Cancer.


The participant group includes women aged 25 to 80 years with no breast surgery in the past year and no previous cancer diagnosis except non-melanoma skin cancer. Blood samples are collected around the time of screening mammography and before any biopsies or surgeries.

Interested in joining our clinical study? Click here

One in eight women will develop invasive breast cancer in her lifetime.¹

In 2020, there were 7.8 million women alive who had been diagnosed with breast cancer in the past 5 years.²

About 50% of women have dense or very dense breast tissue, which can result in decreased mammography sensitivity.³

18% of breast cancer diagnoses are women under 50-years-old, below the recommended screening age. ⁴

Breast cancer is the world’s most prevalent cancer.⁵

Syantra DX | Breast Cancer has an inferred 98.5% accuracy for women under 50-years-old in ongoing prospective clinical studies.⁶

Test performance⁶

Syantra DX™ Breast Cancer has been developed over the past decade and has gone through multiple validations, including an ongoing prospective, blinded international study. This study is enrolling women aged 25-80 years around the time of a screening mammogram. Exclusion criteria include previous cancers and breast surgeries in the past year.

Women under 50*
Syantra breast cancer blood test prediction accuracy

Accuracy

Inferred 98.5% accuracy for women under 50.⁴

Syantra breast cancer blood test prediction sensitivity

Specificity

(ability to detect “no cancer”)

Syantra breast cancer blood test prediction specificity

Sensitivity

(ability to detect “cancer”)

Whole cohort: women age 25 to 80 years*
Syantra breast cancer blood test prediction accuracy

Accuracy

Inferred 92.2% accuracy for women aged 25-80 years .⁴

Syantra breast cancer blood test prediction sensitivity

Specificity

(ability to detect “no cancer”)

Syantra breast cancer blood test prediction specificity

Sensitivity

(ability to detect “cancer”)

*Results presented at the San Antonio Breast Cancer Symposium on December 8, 2021 from an interim analysis of IDBC Clinical Study samples from 1,107 participants. Performance metrics are reported for the blind test set with 99.5% confidence intervals (CI) computed through an exact binomial test. There is the potential for false negative and false positive results to occur.

Announcements and stories

Syantra press release graphic dated November 14, 2023
14 Nov, 2023
Syantra announces additions to their Intellectual property (IP) portfolio as well as a strategic partnership with Limmi, a US-based technology company using AI-driven insights to power next generation disease detection and management techniques. These achievements mark significant milestones for Syantra and represent major advancements in understanding human disease.
01 Nov, 2023
CALGARY, AB. - Today, Syantra, a liquid biopsy platform and innovation company that is changing the way cancer is detected, starting with Syantra DX™ Breast Cancer , announced that Rob Lozuk has been appointed as Chief Executive Officer, effective November 1, 2023. “Rob brings over 23 years of experience successfully scaling and transacting commercially disruptive technologies across the healthcare landscape,” said Kristina Rinker, PhD, Chief Scientific Officer and Co-founder of Syantra. “We are thrilled to add an accomplished world-class executive to our leadership team to elevate our pivotal work in blood-based cancer detection. Rob will bring substantial value to our organization as we expand into the United States with commercial introduction of the Syantra DX™ Breast Cancer test, a blood test that identifies individuals who may have breast cancer, including early-stage disease.” “The existing early cancer detection liquid biopsy paradigm is not adequate, economical, or scalable. Entirely too many early-stage cancers are still being missed, at a time when the opportunity for intervention and survival is the greatest. Truly disruptive healthcare technologies are generational – and that’s exactly what Syantra’s liquid biopsy platform will become” states CEO of Syantra, Rob Lozuk, and adds, “I’m thrilled to be joining the Syantra team at this critical juncture in the liquid biopsy arena. Our AI-powered RNA-based liquid biopsy platform represents a revolution for the screening and detection modalities by measuring a key shift in the body’s immune response that allows cancer to develop. We will rapidly expand the clinical data of the Syantra DX™ Breast Cancer blood test over the remainder of 2023 in preparation for broad global commercialization in 2024.” Within the precision biotech space, Syantra’s liquid biopsy platform has already demonstrated impressive performance statistics as exemplified in the Analytical and Clinical Performance from the Early Analysis of the International Identify Breast Cancer (IDBC) Study, presented by Professor Nigel Bundred, Surgical Oncologist with the Manchester University NHS Foundation Trust, Wythenshawe Hospital, at the 13th European Breast Cancer Conference in Barcelona, Spain, in November of 2022. About Rob Lozuk Prior to joining Syantra, Rob was the Chief Business Officer at Cardea Bio, which culminated in a sale to Paragraf in 2023. Rob was also the President of Specific Diagnostics, which was sold to bioMérieux in 2022. As a public company officer, Rob led the global commercial and operating businesses at Sequenom, a pioneer in revolutionizing the prenatal space, which was successfully transacted to Lab Corp (LH). Prior to Sequenom, Rob was the P&L leader for ThermoFisher Scientific’s Advanced Staining Business and served as Director of Sales, Marketing and Business Development. About Syantra, Inc. Syantra is a precision biotechnology company changing the way cancer is detected and treated with revolutionary high-performance blood-based tests providing a new way to help detect cancer. Syantra’s scalable, patent-protected platform is based on changes in the immune system and other systemic factors that occur when a cancer tumor is present. These changes can be measured through mRNA biomarkers that are contained in a small amount (2.5ml) of blood. When biomarker expression is combined with patient characteristics, there is a high correlation to the presence or absence of disease. The Syantra platform includes a custom real-time PCR process with proprietary software that includes machine learning-based algorithms. Syantra’s blood testing platform provides a cost-effective way to help identify individuals who may have cancer and should be further evaluated. About the Syantra DX™ Breast Cancer test Syantra is changing the way cancer is detected and treated. Its flagship product, Syantra DX™ Breast Cancer , is a minimally invasive and high-performance blood test for the detection of breast cancer signals at the earliest stages, when breast cancer is easier to treat. The Syantra DX™ Breast Cancer test will be available to women in Canada and the United States in early 2024.
Cara Campbell, breast cancer survivor, poses for a photo with her grandson, Rhett.
22 Aug, 2023
At age 29, Cara woke up with a small lump on her chest. Cara made sure to visit her doctor right away for a thorough breast exam and mammogram. Two weeks later, after an ultrasound and a biopsy, Cara was diagnosed with breast cancer.
Katie Smith-Parent, stage two hormone-positive breast cancer survivor,  smiles in her kitchen.
25 May, 2023
In her early 30s, Katie Smith-Parent noticed a lump on her breast. She was initially told by a doctor not to worry and that the lump would go away on its own. She trusted her instincts and after finding a new doctor, she was diagnosed with stage two hormone-positive breast cancer. Today, she is an advocate for early detection and oncofertility.
Syantra Press Release graphic dated April 18, 2023
18 Apr, 2023
Syantra announced today that it has obtained CE marking for the Syantra DX™ Breast Cancer test. Syantra DX™ Breast Cancer is a minimally invasive blood test for the detection of an active breast cancer signature - in the earliest stages when it is easier to treat. Securing CE marking allows the company to market the blood test in the European Union and other countries that recognize the designation.
Olesya Kharenko stands in front of Syantra lab in lab coat.
08 Feb, 2023
The typical career journey for a scientist is fairly linear. But a lens focused on only one speciality can make it challenging to leverage the many ways these disciplines can crossover. Imagine the possibilities of a single scientist who brings expertise from more than three disciplines to research. Syantra found that in Olesya Kharenko, PhD.
Show More

Accreditations and regulatory certifications

As a precision medicine company, quality systems are the backbone of everything we do. We work with regulatory authorities and accrediting organizations worldwide to ensure that our processes and protocols are up-to-date and consistently meet the highest standards. Learn more about our accreditations and regulatory certifications.

Please note

Syantra DX™ Breast Cancer is a screening test and may be used as part of the regular screening process. There is the potential for false negative and false positive results to occur. All results should be interpreted by a qualified healthcare provider, and no interventional action should be taken based solely on Syantra DX™ Breast Cancer results.

Citations

  1. SEER Cancer Statistics Review, 1975-2017, 2020.
  2. World Health Organization. “Fact Sheets/Detail/Breast Cancer.” March 2021.
    www.who.int/news-room/fact-sheets/detail/breast-cancer
  3. Thigpen D, Kappler A, Brem R. The Role of Ultrasound in Screening Dense Breasts-A Review of the Literature and Practical Solutions for Implementation. Diagnostics (Basel). 2018;8(1):20. Hendrick RE, et al, DMIST Investigators Group. Radiology. 2008 Feb; 246(2):376-83. Kolb TM, et al. Radiology. 2002 Oct; 225(1):165-75.
  4. DeSantis, C.E. et al., 2019. Breast Cancer Statistics CA: A Cancer Journal for Clinicians. 69: 438.
  5. World Health Organization. “Fact Sheets/Detail/Breast Cancer.” March 2021.
    www.who.int/news-room/fact-sheets/detail/breast-cancer
  6. Syantra DX™ Breast Cancer has been evaluated in clinical studies for women between the ages of 25 and 80. The data infers an accuracy of 92.2% for women between 25 and 80, and 98.5% for women under 50. See IDBC study on clinicaltrials.gov: Bundred, N. et al., A whole blood assay to identify breast cancer: interim analysis of the international identify breast cancer (IDBC) study evidence supporting the Syantra DX™ Breast Cancer Test, San Antonio Breast Cancer Symposium, 21-A-1625-SABCS, presented December 8, 2021, San Antonio, TX, USA.

Contact us

Interested in learning more about Syantra DX™ Breast Cancer or Syantra Inc.? Contact us through the form below.

Syantra Inc.

1-877-331-0516

105 - 32 Royal Vista Drive NW 

Calgary, Alberta

T3R 0H9

Canada

Share by: